Evidence map›Paper›PMID 29075651›Full record

ArticleJournal of cancer stem cell research2017

Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells.

Ashley N Gilbert, Kiera Walker, Anh Nhat Tran, Nathaniel H Boyd, G Yancey Gillespie, Raj K Singh, Anita B Hjelmeland

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Cancer Explant Models.Current topics in microbiology and immunology · 2021
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ashley N GilbertVivo Biosciences Inc., Birmingham, AL.
Kiera WalkerDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL.
Anh Nhat TranDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL.
Nathaniel H BoydDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL.
G Yancey GillespieDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL.
Raj K SinghVivo Biosciences Inc., Birmingham, AL.
Anita B HjelmelandDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL.
University of Alabama at Birmingham · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMASP20CA151129 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY · 2011 to 2013
$2.3M
Training Program in Brain Tumor BiologyT32NS048039 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BENVENISTE, ETTY N · 2007 to 2017
$2.0M
A20 Promotes Glioma Stem Cell Mediated TumorigenesisR01CA151522 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HJELMELAND, ANITA BORTON · 2010 to 2014
$1.2M
Identification of Glucose Transporter 3 Inhibitors for Glioblastoma TreatmentR21NS096531 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AUGELLI-SZAFRAN, CORINNE ELIZABETH, HJELMELAND, ANITA BORTON · 2016 to 2017
$537k
Microenvironmental Regulation of Glioblastoma Angiogenesis via CHD7F31CA200085 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOYD, NATHANIEL · 2015 to 2017
$86k
NCI NIH HHS F31 CA200085NCI NIH HHS HHSN261201500066CNCI NIH HHS P20 CA151129NCI NIH HHS R01 CA151522NIAID NIH HHS P30 AI027767NINDS NIH HHS R21 NS096531NINDS NIH HHS T32 NS048039
6 · The paper itself

Abstract

Development of effective novel anti-tumor treatments will require improved in vitro models that incorporate physiologic microenvironments and maintain intratumoral heterogeneity, including tumor initiating cells. Brain tumor initiating cells (BTIC) are a target for cancer therapy, because BTICs are highly tumorigenic and contribute to tumor angiogenesis, invasion, and therapeutic resistance. Current leading studies rely on BTIC isolation from patient-derived xenografts followed by propagation as neurospheres. As this process is expensive and time-consuming, we determined whether three-dimensional microtumors were an alternative in vitro method for modeling tumor growth via BITC maintenance and/or enrichment. Brain tumor cells were grown as neurospheres or as microtumors produced using the human-derived biomatrix HuBiogel™ and maintained with physiologically relevant microenvironments. BITC percentages were determined using cell surface marker expression, label retention, and neurosphere formation capacity. Our data demonstrate that expansion of brain tumor cells as hypoxic and nutrient-restricted microtumors significantly increased the percentage of both CD133+ and CFSE

Identifiers

PMID29075651
PMCPMC5653320
OpenAlexW2734352535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.